肿瘤细胞治疗研究
英文原题：STING agonist cGAMP enhances anti-tumor activity of CAR-NK cells against pancreatic cancer.
这些结果提示，STING激动剂与NK细胞联合可能成为胰腺癌的一种新型免疫治疗策略。
干扰素基因刺激因子（STING）介导的固有免疫应答的激活已被认为是一种有前景的癌症治疗策略。然而，STING激动剂对胰腺癌中自然杀伤（NK）细胞介导的抗肿瘤应答的影响仍不清楚。在此，我们评估了经典STING激动剂环鸟苷酸-腺苷酸（cGAMP）对胰腺癌中NK细胞的影响。我们发现cGAMP可直接激活NK细胞并增强胰腺癌细胞对NK细胞细胞毒作用的敏感性，提示cGAMP可能成为NK细胞治疗的潜在佐剂。此外，靶向间皮素的CAR-NK-92细胞与cGAMP联合应用通过抑制肿瘤生长和延长胰腺癌小鼠模型的生存期，显示出更强的抗肿瘤疗效。这些结果提示，STING激动剂与NK细胞的联合可能成为胰腺癌的一种新型免疫治疗策略。
Activation of the stimulator of interferon gene (STING)-mediated innate immune response has been suggested as a promising therapeutic strategy for cancers. However, the effects of STING agonist on natural killer (NK) cell-mediated anti-tumor responses in pancreatic cancer remains unknown. Herein, we evaluated the effects of a classical STING agonist cyclic GMP-AMP (cGAMP) on NK cells in pancreatic cancer. We found that cGAMP could directly activate NK cells and enhance the sensitivity of pancreatic cancer cells to NK cell cytotoxicity, suggesting that cGAMP may become a potential adjuvant for NK cell therapy. In addition, combination of CAR-NK-92 cells targeting mesothelin and cGAMP displayed greater antitumor efficacy by inhibiting tumor growth and prolonging survival of the mouse model of pancreatic cancer. These results suggest that the combination of a STING agonist and NK cells may become a novel immunotherapy strategy for pancreatic cancer.
MEMBER ACCOUNT
登录成功会直接打开下一页。
